<DOC>
	<DOCNO>NCT02730442</DOCNO>
	<brief_summary>This open label study two part . In first part , F901318 ( dose 2 mg/kg IV 4 hour , Day 1 ) follow F901318 ( 2 mg/kg IV 4 hour ) give Day 8 , dose fluconazole 800 mg daily 1 day ( Day 4 ) 400 mg daily orally 4 day ( Days 5 8 ) . Up twenty subject include two cohort undergo dose schedule fluconazole F901318 undergo procedure . The first cohort consist 12 subject study two group six subject . If clearly difference F901318 kinetics detectable dose fluconazole first cohort , second cohort study . If clear difference , second cohort also study give final result . In cohort , base pharmacokinetic finding cohort 1 , dose F901318 may increase 4 mg/kg establish dose suitable phase 2 evaluation . PK sample plasma F901318 continue first dose include 72 hour dose . PK sample fluconazole continue first dose 72 hour fifth dose . A follow visit conduct 7 +/- 2 day discharge clinical unit follow completion blood sample follow second dose F901318 fifth dose fluconazole . The second part study take place appreciable change pharmacokinetics either F901318 fluconazole observe either first second cohort first part study . This second part enrol 12 subject . These subject receive fluconazole 800 mg daily one day ( Day 1 ) 400 mg daily orally 4 day ( Days 2 5 ) combination F901318 give dose 4 mg/kg IV bid one day ( Day 1 ) follow 7 dos intravenous F901318 2.5 mg/kg bid ( Days 2 5 ) . Pharmacokinetic profile F901318 fluconazole obtain dose 72-hour period follow final dose compound .</brief_summary>
	<brief_title>Study Potential Interaction Fluconazole With F901318</brief_title>
	<detailed_description>Part 1 Treatment Period ( Day -1 Day 11 ; visit 2 ) : Subjects admit clinical unit afternoon Day -1 remain site completion 72-hour post fluconazole F901318 dose study-related procedure Day 11 . Admission procedure ( Day -1 ) include review inclusion/exclusion criterion , weight , vital sign , test drug abuse , alcohol smoking pregnancy appropriate ( must negative ) , review concomitant medication adverse event . Blood ( haematology , clinical chemistry coagulation function ) urine ( urinalysis ) obtain safety evaluation . Breakfast take 30-60 minute prior dose ) Days 1 - 4 : F901318 ( 2 mg/kg IV cohort 1 4 mg/kg IV cohort 2 ) 4 hour administer Day 1 . Blood sample determination plasma level F901318 collect predose follow time point 72 hour post-dose : 1 , 2 , 3 , 4 , 4.25 , 4.5 , 5 , 6 , 8 , 10 , 12 , 16 , 20 , 24 , 38 , 48 , 72 hour Blood pressure , pulse ( lie stand ) , core temperature record follow time Day 1 : Prior dosing , 1 , 2 , 4 , 6 , 8 , 12 24 hour follow dosing . Twelve lead ECGs record prior dose 1 , 4 , 8 , 12 24 hour dose F901318 . Telemetry set 1 hour prior dose F901318 continue 12 hour thereafter . It may extend 24 hour discretion investigator . Day 4 Day 7 : After overnight fast midnight , fluconazole administer dose 800 mg day 4 400 mg daily Days 5-7 morning . On Day 4 , pharmacokinetic blood sample draw fluconazole estimation follow time relation dosing : -5 minute , 15 , 30 , 45 , 60 , 75 , 90 , 120 min . 3 , 4 , 6 , 8 , 10 , 12 , 16 , 20 hour . Blood sample determination peak ( 4 hour ) trough ( predose ) plasma level fluconazole collect Days 5 7 inclusive . Dosing day breakfast take . Vital sign ( supine stand pulse rate blood pressure oral temperature ) record prior dose Day 4 follow time thereafter : 1 , 4 , 8 , 12 , 24 , 48 hour 12 lead ECGs record prior dose Day 4 follow time thereafter : 24 , 48 hour . Fasting blood sample obtain haematology , coagulation clinical chemistry prior dose fluconazole Day 4 follow time point : 48 hour A spot urine sample obtain urinalysis prior dose fluconazole Day 4 follow time point : 48 hour Days 8-11 : Subjects fast 12 hour dose Day 8 . Water allow ad libitum . Blood sample determination baseline plasma level fluconazole F901318 blank safety laboratory analysis ( clinical chemistry , haematology coagulation function ) collect pre-dose Day 8 . F901318 ( 2 mg/kg IV cohort 1 4 mg/kg IV cohort 2 ) administer intravenously 4 hour morning . Fluconazole administer orally Day 8 time start infusion . Blood sample determination plasma level fluconazole collect following time point dose fluconazole : 15 , 30 , 45 , 60 , 75 , 90 min , 2 , 3 , 4 , 6 , 8 , 10 , 12 , 16 , 20 , 24 , 36 , 48 , 72 hour . Blood sample plasma concentration F901318 collect follow time start infusion ( assume infusion duration 4 hour ) . 1 , 2 , 3 , 4 , 4.25 , 4.5 , 5 , 6 , 8 , 10 , 12 , 16 , 20 , 24 , 38 , 48 , 72 hour Blood pressure , pulse ( lie stand ) core temperature record follow time Day 8 : 1 . 2 , 4 , 6 , 8 , 12 24 , 48 , 72 hour follow start dose F901318 . Twelve lead ECGs record 1 , 4 , 8 , 12 , 24 , 48 , 72 hour dose F901318 . Telemetry commence 1 hour prior dose F901318 continue 12 hour thereafter . This monitoring may extend 24 hour discretion Principal Investigator . Adverse event concomitant medication record throughout . Subjects discharge 72 hour measurement observation complete , long fit leave opinion Investigator . Post Study Visit : ( visit 3 ) After discharge Day 11 , subject return study centre day 16-20 complete post study follow-up visit . Total blood loss subject part study 202 mL approximately . Part 2 Treatment Period ( Day -1 Day 8 ; visit 3 ) : Subjects admit clinical unit afternoon Day -1 remain site completion 72-hour post fluconazole F901318 dose study-related procedure Day 8 . Admission procedure ( Day -1 ) include review inclusion/exclusion criterion , weight , vital sign , test drug abuse , alcohol smoking pregnancy appropriate ( must negative ) review concomitant medication adverse event . Blood ( haematology , clinical chemistry coagulation function ) urine ( urinalysis ) obtain safety evaluation . Subjects fast midnight . Day 1 : F901318 4 mg/kg IV 4 hour bid administer starting time 0 fluconazole 800 mg orally time 0 . A second dose F901318 ( 4 mg/kg IV 4 hour ) give start 12 hour post morning dose . Water allow ad libitum . Blood sample determination plasma level F901318 collect predose follow time point : 2 . 4 , 4.25 , 4.5 , 5 , 6 , 8 , 10 , 12 ( second infusion ) , 16 ( 5 minute end infusion ) hour . Pharmacokinetic blood sample draw fluconazole estimation pre-dose follow time dose : 15 , 30 , 45 , 60 , 75 , 90 , 120 min . 3 , 4 , 6 , 8 , 10 , 12 , 16 , 20 hour . Blood pressure , pulse ( lie stand ) , oral temperature record follow time Day 1 : Prior dosing , 1 , 2 , 4 , 6 , 8 12 hour follow dosing . Twelve lead ECGs record prior dose 1 , 4 , 8 , 12 hour dose . Telemetry set 1 hour prior dose F901318 continue 12 hour thereafter . This monitoring may extend 24 hour discretion Principal Investigator . Local tolerability determine prior dose F901318 end infusion . Day 2 Day 8 : F901318 administer intravenously twice daily ( 7 dose 2.5 mg/kg infuse 4 hour ) ( Days 2 5 ) . Fluconazole administer fast 12 midnight dose 400 mg daily morning 4 dos ( Days 2 5 ) . Blood sample determination peak ( 4 hour ) trough ( predose ) plasma level fluconazole F901318 ( prior start infusion 5 minute end infusion ) collect Days 2 4 inclusive . Vital sign ( supine stand pulse rate blood pressure , core temperature local tolerability ) record prior end infusion Days 2 , 3 4 12 lead ECGs record prior morning dosing Days 2 , 3 , 4 5 Fasting blood sample obtain haematology , coagulation clinical chemistry prior dose fluconazole Days 2 , 5 Day 8 ( 72 hour last dos F901318 fluconazole ) . A spot urine sample obtain urinalysis prior dose fluconazole Days 2 , 5 Day 8 ( 72 hour last dos F901318 fluconazole ) . On Day 5 , pharmacokinetic blood sample draw F901318 estimation follow time relation dosing : -5 minute , 2 , 4 , 4.25 , 4.5 , 5 , 6 , 8 , 10 , 12 , 16 , 20 , 24 , 36 , 48 , 72 hour . On Day 5 , pharmacokinetic blood sample draw fluconazole estimation follow time relation dosing : -5 minute , 15 , 30 , 45 , 60 , 75 , 90 , 120 min . 3 , 4 , 6 , 8 , 10 , 12 , 16 , 20 , 24 , 36 , 48 , 72 hour . Vital sign local tolerability obtain prior dose Day 5 end F901318 infusion . Telemetry set 1 hour prior dose F901318 Day 5 continue 12 hour thereafter . This monitoring may extend 24 hour discretion Principal Investigator . Day 8 : An ophthalmology assessment perform . Subjects discharge Unit follow collection final assessment blood sample completion ophthalmology assessment . Adverse event concomitant medication record throughout . Post Study Visit ( visit 4 ) : After discharge Day 8 , subject return study centre day 13-17 complete post study follow-up visit . Total blood loss subject part study 224 mL approximately .</detailed_description>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<criteria>1 . Subjects males female ethnic origin age 18 45 year age weigh 50100 kg inclusive . 2 . Subjects must good health , determine medical history , physical examination , 12lead electrocardiogram ( ECG ) clinical laboratory evaluation ( congenital non haemolytic hyperbilirubinaemia acceptable ) . 3 . Subjects give write informed consent participate study abide study restriction . 1 . Male female subject willing use appropriate contraception study three month thereafter . 2 . Subjects receive prescribed systemic topical medication within 14 day dose administration unless opinion Investigator Medical Monitor medication interfere study procedure compromise safety . 3 . Subjects use nonprescribed systemic topical medication ( include herbal remedy ) within 7 day dose administration ( exception vitamin/mineral supplement paracetamol ) unless opinion Investigator Medical Monitor medication interfere study procedure compromise safety . 4 . Subjects receive medication , include St John 's Wort , know chronically alter drug absorption elimination process within 30 day dose administration unless opinion Investigator Medical Monitor medication interfere study procedure compromise safety . For least 2 week prior dose blood sample observation complete Day 18 +/ 2 ( Part 1 ) Day 15 +/ 2 ( Part 2 ) , subject allow eat food drink beverage contain alcohol , grapefruit grapefruit juice , apple orange juice , vegetables mustard green family e.g . kale , broccoli , watercress , spring green , kohlrabi , Brussels sprout , mustard charbroiled meat .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>